ADCT vs MTD · rev $70.8M vs P/E 27, rev $3.87B
ADC Therapeutics SA (ADCT) versus Mettler-Toledo International Inc (MTD) — a side-by-side from cached financials, not a winner call.
ADC Therapeutics SA (ADCT) is a biotechnology company listed on NYSE.
Mettler-Toledo International Inc (MTD) is a diagnostics & research company listed on NYSE.
Latest reported ADCT revenue for 2024-12-31 was $70.8M. Net income was -$157.8M. Revenue was up 1.8% from 2023-12-31 to 2024-12-31. ADCT currently screens at market cap $141.2M.
Latest reported MTD revenue for 2024-12-31 was $3.87B. Net income was $863.1M. Revenue was up 2.2% from 2023-12-31 to 2024-12-31. MTD currently screens at market cap $23.20B and trailing P/E 26.9.
ADCT currently screens at market cap $141.2M. MTD currently screens at market cap $23.20B and trailing P/E 26.9.
Not investment advice. Open the ADCT and MTD stock pages for the full models.
Not investment advice.